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Congestive heart failure: Treat the disease, not the
symptom—Return to normalcy
Gerald D. Buckberg, MD
Pathology is the dilemma that physicians confront daily in patient care.The consequences of any distortion of structure become the symptomsof the disease created by abnormal processes. Treatment is directedtoward alleviation of these results that “remodel away” from normalstructure and biochemistry. This confrontation over symptoms occursin the health care community (medicine, surgery, pharmacology,
medical devices, and through annual health care costs). Medical students cannot
wait to leave their learning curve–established normal principles. To many, these are
an astounding roadblock between the basic and clinical areas. The obligatory study
of normality is a “brief hurdle” they must pass on the real road to becoming a
physician. Fundamental basic sciences are thought to reflect the unimpeachable
camp of the “preclinical school.” The motivational objective is to deal with the
dilemma of the sick patient.
The purpose of this report is to show that departure from normality and lack of
focus on its importance are very expensive and less effective ways to deal with
pathologic conditions. The result of this focus on abnormality caused by disease is
an explosive development of drugs, operations, machines, and health care personnel
to minimize the physical and biochemical derangements of such diseases. A prom-
inent example is congestive heart failure (CHF), which affects 4.9 million persons
in the United States. The disease constitutes loss of the normal elliptical ventricular
architecture, to produce a dilated spherical ventricle with limited contractile and
filling capacities. The consequences are fatigue, pulmonary congestion, associated
arrhythmias, repeated hospitalizations, and eventually death.
The pathologic derangement is called remodeling due to heart diseases in which
the blood flow, valve, and muscle itself are damaged. This term remodel is used
extensively in medical and surgical circles to define the diseased state, but the
definition of this word does not appear in many dictionaries. Its antonym is
unhealthy or away from normal. The word restore is also absent from the literature.
This is defined as “will bring things back to normal.” I use the term restore and hope
its understanding creates a paradigm shift that may change current treatments of
pathologic conditions.
CHF is a change from the normally elliptical left ventricular shape to a spherical
dilated muscle, in which the fiber angle for normal contraction is lost and the natural
tightness between excitation and resulting contraction becomes abnormal. The
collagenase architecture surrounding the muscle, including nerves and vessels,
becomes diminished by this distention. Dilatation raises metabolic needs and may
cause ischemia because of abnormal flow distribution.1
The distended, dilated muscle initiates a biochemical reaction in the renin-
angiotensin and sympathetic systems. Abnormal levels of angiotensin are present in
the renin-angiotensin system to combat distention and produce hypertrophy of
working muscle. The sympathetic nervous system is stimulated to increase blood
pressure by vasoconstriction to supply organs and enhance heart rate to maximize
output. Additionally, aldosterone levels are elevated to cause peripheral constriction
to maintain blood pressure and enhance scarring. Reduced urine output results from
diminished renal blood flow and sodium retention, and a change in collagen content
of the heart produces dilatation by collagenase stimulation through distention.
The medical treatments of these consequences are angiotensin-converting en-
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zyme inhibitors (limiting collagen breakdown), -blockers
(decrease sympathetic tone), spironolactone (decreases al-
dosteronism and fibrosis), and diuretics like furosemide
(Lasix) to enhance urinary blood flow and produce decom-
pression of retained fluid. These treatments prolong life
expectancy in patients with CHF and help to reduce the
classification of CHF from class IV to class II-III. This
reflects a moderate enhancement in activities and a right-
ward shift of the mortality from the 50% 5-year mortality,
yet it allows an ongoing downward trend in which, at
present, 50% of persons with CHF now live for 8 years. The
end result is the same overall mortality, with fewer symp-
toms and prolonged health care.
Hospitalizations are frequent in patients with class III
and class IV CHF, approximately 2 million in 1 year, and
approximately 50% of such patients need rehospitalization.
The cost today is $100 billion per year to Medicare and
private insurance providers. By 2020 the cost will exceed $1
trillion per year, as the number of patients older than 65
years will double. This astronomical expense has stimulated
the National Institutes of Health, Health Care Financing
Administration, pharmacologists, and drug companies to
deal with the symptoms of CHF. There is marginal interest
in the disease itself: the role of changing the anatomy of the
dilated ventricle.
The electrical approach to the sphere includes a wrap-
ping of the diseased muscle, called cardiomyoplasty, to
prevent dilatation. Electrical defibrillators are implemented
to treat arrhythmias caused by this distention. Right ven-
tricular pressure and then pulmonary artery pressure (re-
flected from right ventricular pressure) are monitored to
detect early signs of pulmonary congestion caused by de-
creased left ventricular emptying. This may limit early
rehospitalization before CHF advances to a later stage.
Additionally, biventricular electrical pacing restores normal
septal contraction as excitation/contraction delay follows
distention. These abnormalities occur in both normal mus-
cle (that can recover) and abnormal muscle. The recovery
reflex in electromechanical abnormality is corrected by by-
passing slower conduction with direct septal, right ventric-
ular, and left ventricular stimulation.
Surgical treatment follows the same rightward shift of
decreasing mortality, yet the downward curve persists. Re-
vascularization alone enhances survival, and long-term
mortality relates to preoperative ejection fraction. At 10
years, survival was 20% at an initial ejection fraction of
25% and about 40% at an initial ejection fraction of 35%.2
Augmented blood flow relieves angina, but the downward
mortality trend persists. A similar prognosis follows valve
replacement or repair for valve insufficiency in dilated or
ischemic cardiomyopathy. Restoring mitral valve compe-
tence by valve replacement (without coronary disease) in
patients with an ejection fraction of less than 40% yields a
60% mortality at 10 years3; after valve repair, the 5-year
mortality is 50% in patients with ischemic and dilated mitral
incompetence.4
This symptomatic treatment displaces the mortality
curve to the right by altering the downward trend. Patients
require frequent visits from nurses to start inotropic drugs to
improve cardiac output and prevent rehospitalization. Exer-
cise capacity in patients who have a dilated heart remains
limited. Repeated hospitalizations are required to treat re-
current CHF. These limitations account for an astounding
health care cost.
Alternate surgical methods to deal with the fatiguing
heart include mechanical displacement of the failing ventri-
cle with a left ventricular assist device. These devices in-
volve expensive initial costs, can become infected, and can
generate clots because of the absence of an endothelial
covering. They reduce the symptoms of CHF but do not
function for a prolonged period. They are not available in all
centers and require substantial monitoring. The final step,
transplantation, is limited by restricted organ availability
and subsequent rejection and immunosuppressive treatment
to avoid rejection. The treatment for rejection itself includes
complications, such as coronary artery disease and tumor
formation.5,6
The Diagnostic Dilemma
The approach to the symptoms versus the disease is most
evident during characterization of the diagnosis of the
pathologic abnormality that reduces left ventricular function
and produces CHF. Attention is directed toward how blood
is ejected, rather than toward the underlying left ventricular
volume and shape responsible for diminished heart func-
tion. Everyone accepts that a low ejection fraction is abnor-
mal and recognizes that the heart must deal with this to
maintain cardiac output by dilating. Fatigue is recognized as
a limitation of decreasing reserve by ventricular dilatation.
Unfortunately, attention is seldom paid to the left ven-
tricular volume itself, the spherical underpinning of CHF.
This provides a classic example of this fundamental di-
lemma, a misunderstanding of the disease despite routine
assessment of the left ventricle by ventriculography. This
critical information is routine during cardiac catheterization
to evaluate for ejection fraction, yet determining left ven-
tricular size has not achieved the critical role it deserves in
the CHF entity.
The right anterior ventricular view of left ventricular
function is routine or sometimes excluded because of echo-
cardiographic study. Biplane ventriculograms that clearly
characterize both ejection fraction and global volume are
seldom obtained. Magnetic resonance imaging (MRI) mea-
sures left ventricular size and is available but not used in
most institutions. The current pattern of left ventricular
evaluation persists despite important knowledge of the
value of ventricular volume made available since 1987 from
Editorials Buckberg
S42 The Journal of Thoracic and Cardiovascular Surgery ● March 2003
White and associates7 (Figure 1). There is a close correla-
tion between increased volume and progressive mortality
that is independent of evaluating ejection fraction in many
patients (Figure 2).7
The value of end-systolic volume indices is unknown to
many physicians and surgeons, even though their value has
been recognized. Gaudron,8 Di Donato,9 and their associates
reinforced the concept by showing how both changing and
altering the left ventricular size affects muscles whose fiber
orientation is changed surgically to create a more normal
ellipse. This geometric approach excludes muscle affected
by myocardial infarction that cannot recover because of
akinesia.
The value of left ventricular end-systolic volume index
(LVESVI) versus ejection fraction is further characterized
by Yamaguchi,10 Vanovershelde,11 and their colleagues.
Unfortunately, these fundamental manuscripts are not in the
database of many leaders in the treatment of CHF. Data
developed in CHF clinics and worldwide symposiums to
deal with the manifold symptoms of CHF persist with this
disease. Our patients sustain exhaustive and unfathomed
tests that characterize the consequence of low output syn-
drome from the damaged muscle. The concept of sphericity
is recognized but rarely calculated. There is emphasis on the
diastolic spherical index rather than on systole when ejec-
tion fraction occurs. Articles on CHF that do focus on the
spherical heart often do not emphasize the essential con-
traction and suction properties of the ellipse.
The National Institutes of Health has exhibited extraor-
dinary interest in CHF. Many of its conceptual leaders focus
on the special position of individual knowledge and the
“unique responsibility of a certain gene of CHF.” A broad
extent of genetic factors is stimulated by the “process of
CHF,” but the capacity to focus on a single factor may
reflect a real limitation of focal knowledge in understanding
the disease.
The first step is to understand the true central theme, the
spherical dilated ventricle as the causative factor. As phy-
sicians, we must recognize that remodeling only enlarges
our understanding of this abnormal area. The symptom
purveys each patient study of regulated responses and cap-
tures our diagnostic and therapeutic interest. The impor-
tance of the novel objective to restore the geometry to a
more normal ventricular shape should be recognized. Re-
building fundamental fiber orientation structure will allow
more normal muscle function. This is the true end point of
our therapeutic approaches. Treat the disease, not the symp-
tom.
This criterion of unifocalization is known as knowledge,
and this is defined as “taking apart” or differentiating or
analyzing approaches. Of course, the result will be an as-
tounding expertise in one aspect of CHF, but where is the
communication between other aspects and this observation?
In and of themselves, they will not and cannot deal with any
interconnected factors. The synthesis of key points of the
aforementioned factors are then “put together” for integra-
tion. This solution is called wisdom. These concepts are
drawn together by a vast degree of underlying knowledge.
To do this, we must separate ourselves from the isolated
expertise and then use a broad understanding of all aspects
of individual factors toward the solid solution that is imple-
mented.
Our role is to control symptoms after normal geometry is
restored, not to displace correction of the problem. Conven-
tional approaches deal with the vessels supplying blood to
normal muscle, the secondary changes of the ventricle that
cause valve insufficiency, but not with the abnormal ven-
tricle directly.
Figure 1. The relative risk for death after myocardial infarction,
depicted as the relationship between LVESV and survival. The
volume index is approximately 50% of end-systolic volume, or
25  10 mL/m2. (From Colucci WS, editor. Atlas of heart failure:
cardiac function and dysfunction. 2nd ed. Philadelphia: Current
Medicine, Inc; 1995, 1999; adapted from White et al.7 Reprinted
with permission.)
Figure 2. The relationship between LVESVI and ejection fraction.
There is correlation, but great overlap (r2  0.29. These values
were described by Di Donato and Dor (Centre Cardiothoracique
de Monaco, 2000) in patients undergoing restoration.
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At this time, these architectural changes can occur by
surgical correction. In that surgical correction process, we
cannot superimpose more intraoperative damage during res-
toration. Unless intraventricular injury from poor protection
is avoided, preventable changes will markedly limit the
influx of medical/surgical participation in this process and
thereby exclude the use of surgical procedures that correct
CHF.
The Evolution
The history of our organized escape from understanding
normalcy is the 1-year allocation of time for the learning of
normalcy (ie, the first year of medical school). This is
followed by a 3-year drive to see pathologic conditions,
understand them, learn them, and treat them. This informa-
tion is used for the remainder of medical school training and
throughout the physicians’ medical lives. The remodel end
point becomes our starting point. Some think it is a failure
to return to the point of initial escape—the normal heart.
In the heart, for example, we learn about constriction for
systole, as described by Harvey, and about dilatation for
diastole, also described by Harvey. The concept of twisting
and untwisting are unknown to many physicians and sur-
geons, even though they are precisely how the heart ejects
and sucks to fill. These concepts date back to the Greeks,
with Erasistratus and then Galen. They were discarded by
Harvey, who was simply incorrect. Borelli described the
heart as a rope with a vortex or spiral of fibers and clarified
that ejection was like twisting a rope to wring out blood.
Anatomists like Vesalius, Mall,12 and others showed that
muscle structure for twisting and untwisting occurs. Only
with MRI can we now characterize this more precisely.
Despite these factors that define normalcy, they are rela-
tively unknown to those who practice medicine, surgery,
and treat CHF throughout the health care community.
Instead, the ejection fraction is fundamental, with a near
complete absence of either measuring the LVESVI or, more
importantly, understanding its meaning when its vital value
is given along with the conventional ejection fraction re-
cording. The focus is on a specific number (ie, ejection
fraction) rather than on understanding the concept of how
the ellipse works to improve function and where fiber angle
(not ejection fraction) is critical. This focus defeats our
progress. Many experts know calcium, ionic balance, mus-
cle fiber kinetics, electrophysiology, molecular biology, and
neuroendocrine responses. Each factor is important, but
coalition of these entities is needed.
The Present: A New Focus on the Akinetic Heart
Surgeons and cardiologists read but do not listen to the
geometric solutions suggested by Jatene and Dor and
Cooley to return ventricular shape toward an elliptical form.
Others in the CHF community are unaware of these efforts.
To some, this seems like an “all too simple solution.”
Perhaps that is the answer, for nature is simple. It is scien-
tists who are complicated, as suggested by Torrent-Guasp
(personal communication). We need to learn from under-
standing normality. The way to understand normality is to
remove the current focus only on the pathologic remodeled
aspect caused by disease.
The anatomic dilemma of CHF is a dilated ventricle. In
coronary artery disease, especially with anterior infarction,
there is replacement of the anterior wall and septum with
either a scar or akinetic muscle with marginal salvage of
epicardial regions after reperfusion. There is no aneurysm,
but a nonfunctional muscle is left in place. The disease of
CHF is related to dilatation of the remaining remote muscle.
Its compensatory hypertrophy becomes diminished if coro-
nary artery disease affects vessels supplying functional seg-
ments. The later onset of mitral regurgitation is due to
increased ventricular distention. A restrictive valve defect
develops with or without annular dilatation and compounds
the symptoms. The conventional approach to restoring
blood supply and mitral valve competence must become
amended by rebuilding left ventricular geometry.
The surgical approach in this spherical formation is to
exclude the noncontractile area with a patch or direct suture
to delete apical and septal loss. The septum always must be
excluded if it is diseased. This is a novel surgical approach,
especially with nonscarred muscle, as occurs frequently
with reperfusion with trabeculated muscle salvage without
function. This results in alteration of left ventricular shape
to restore an elliptical formation. This resultant geometric
change reduces wall stress by limiting radius and increasing
thickness. Simultaneously, there is increasing deformation
of strain produced by more normal muscle fiber orientation.
An Alternate Objective: The Restored Ventricle
CHF occurs in 4.9 million patients in the United States and
69% have coronary artery disease. Among them, 90% have
a myocardial infarction, which results in loss of regional
contraction and thereby altered cardiac structure/function
relationships. The geometric consequence is loss of the free
wall and underlying septum. Left ventricular ejection pre-
dominantly is caused by longitudinal shortening relying on
obliquely oriented fibers. There is conversion of normal
elliptical shape with oblique fiber orientation (where 15%
shortening causes 60% ejection fraction) to a spherical
chamber where a more transverse fiber orientation reduces
contractile forces (ie, 15% fiber shortening causes 30%
ejection fraction) in remote viable muscle.13 MRI studies
show that myocardial stress and strain reduce and decrease
contractile shortening in remote myocardium (ie, from 15%
to 10%) so that ejection fraction is lowered accordingly.14
Progressive dilatation of remote muscle further reduces its
contractile force and increases CHF and mortality, depend-
ing on ultimate left ventricular size.7,8,10,15,16
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The prognosis of CHF after myocardial infarction is
related to the volume and shape changes of the left ventricle.
Regional infarction of more than 30% of left ventricular
circumference causes progressive dilatation of remote via-
ble muscle that tends to convert the normal elliptical left
ventricular shape to a sphere.17 The normal LVESVI of 25
mL/m2 increases to exceed 60 mL/m2 when more than 40%
of muscle becomes nonfunctional. However, an LVESVI of
more than 45 mL/m2 often progresses to cause clinical
CHF.7,8,15-18 This onset of clinical symptoms may develop 6
months to 3 years after acute myocardial infarction as the
remote muscle dilates.8,15 However, the propensity for CHF
can be predicted by LVESVI measured 90 minutes after
myocardial infarction.15 Assessment of left ventricular size
at 12-month intervals after myocardial infarction is predic-
tive of CHF and mortality.16 In patients first assessed at a
time remote from the acute episode, a resting LVESVI of
more than 60 mL/m2 reflects a threshold likely to be asso-
ciated with subsequent cardiac mortality.15
The surgical approach to scar is established, with 6% of
patients who have coronary bypass surgery also undergoing
aneurysmectomy. In the past, the conventional surgical de-
cision to address the segment intraoperatively was based on
how much scarred noncontracting segment collapsed (ie,
dimpled) during left ventricular decompression, signifying
that transmural scarred segment. Initial surgical procedures
only excluded the bulging segment, as described by Cooley
and associates18a in 1959—the linear approach that did not
exclude the aneurysm. There was negligible approach to the
akinetic left ventricle, because exclusion of only anterior
wall, without the septum, did not improve CHF symp-
toms.19 More recently, the entire thinly scarred region has
been excluded, including the free wall and septum, through
the work of Jatene20 in 1984, imbricating the scarred region,
Dor, Kreitmann, and Jourdan21 in 1984 (intraventricular
patch), Cooley and associates22 in 1989 (endoaneurysmec-
tomy), and Mickleborough and colleagues23 in their article
in this Journal.
Currently, thrombolytic treatment and percutaneous an-
gioplasty for acute myocardial infarction have decreased
aneurysm formation so that the scarred left ventricle, espe-
cially with dyskinesia, is uncommon. The “open artery”
concept produces a wave front of death starting in the
endocardium. Recent MRI studies by Bogaert and associ-
ates24 confirm the epicardial viability and underlying necro-
sis of the inner two thirds of the left ventricular wall. A
family of damage develops, with 80% to 90% of contractile
muscle in the endocardium and midmyocardium lost, cov-
ered by a veneer of epicardial salvage to prevent the exten-
sive remodeling with aneurysm formation. However, the
incidence of CHF rises progressively, as the akinetic (non-
contractile) left ventricle remains and progressive remote
dilatation occurs. The infarcted noncontractile section re-
mains akinetic and still involves the free wall and septum,
but operatively has a normal surface from epicardial sal-
vage. We must now focus on this akinetic segment.
Surgical Technique
Ventricular reduction surgery is termed surgical ventricular
restoration and follows the format of established ap-
proaches to ventricular scar established by Dor, Jatene, and
Cooley and now used in aneurysm surgery. The procedure
changes the spherical left ventricular characteristics of CHF
to a more normal elliptical shape to lower wall stress and
enhance thickening of remote viable muscle, through in-
creasing deformation (ie, torsion), by producing a more
helical fiber orientation.
The straightforward surgical approach, before infarct re-
vascularization (ie, open coronary artery), was with the
nonfunctional transmural scar that dimpled during left ven-
tricular decompression (venting) to clarify the “free wall”
part of injured muscle. The primary approach was toward
aneurysms (bulging segment). More recently, these ap-
proaches have been applied to thin akinetic (nonparadoxi-
cal) scars, as well as conventional aneurysms.20-22 There has
been restricted approach to the septum. Aspiration defines
only transmural scar, but it does not describe the nonfunc-
tional region that causes CHF. Attention to only the thin
wall limits septal exclusion, as occurred in only 12% of
Mickleborough’s cases,23 compared with exclusion of 100%
in an approach described by Dor25 and Jatene.20 Micklebor-
ough achieved a 6% increase in ejection fraction after
restoration of akinetic hearts without septal exclusion versus
Dor’s 18% increase in ejection fraction by excluding the
septum and 40% reduction in size.25
Because of thrombolysis or percutaneous transluminal
coronary angioplasty, there is now salvage of epicardial
muscle, preventing dyskinesia (ie, paradox), yet MRI evi-
dence of necrosis of the inner shell of midventricular and
endoventricular muscle persists.14 Akinesia is evident on
ventriculogram, echocardiogram, and MRI, yet the epicar-
dial surface, surgically, is normal with occasional trabecular
scar. The akinetic wall does not collapse during left ven-
tricular venting, yet the decision for exclusion of the non-
functional free wall and septum is made preoperatively,
through nonfunction documented by dynamic assessment
(ventriculogram, echocardiogram).
The left ventricle can be opened with conventional car-
dioplegic approaches (used for coronary bypass grafting and
mitral valve repair when needed) to define an endocardial
scar. Absence of visible scar is not problematic, because the
aortic clamp is removed to allow the heart to beat so that
digital palpation (not vision) allows decisions about sepa-
ration between noncontracting free wall and septum and
furthermore documents viable contracting remote muscle
(ie, inferior or lateral wall and septum) that was made
dysfunctional by myocardial stretching. This digital (not
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visual) separation allows a circumferential Fontan stitch to
be placed to reduce cavity size and create a “surgical neck”
for exclusion of noncontracting free wall and septal non-
functioning regions. The ellipse is restored by inserting an
oval patch (Dacron, pericardium, septal flap), or by using
interrupted sutures to deal with the nonscarred, nonfunc-
tional, more muscular suture bed.
The technique of placing sutures into muscle rather than
scar may include interrupted sutures with pledgets for he-
mostatic security. This mechanical technique is firmly es-
tablished surgically, as the method mirrors, precisely, what
is used for valve replacement. Here, the oval orifice within
the ventricle, without moving parts, becomes substituted for
the valve orifice when a prosthesis is placed in patients with
valve disease. The surgical oval site and suture techniques
are commonplace. There is no risk for air embolism in the
beating open heart, as this technique has been used for many
years with antiarrhythmic approaches during intraventricu-
lar surgery.
The improved myocardial protection afforded during res-
toration by either conventional cardioplegia or the beating
state becomes coupled with rebuilding a more normal ellip-
tical geometry to augment ejection fraction intraoperatively
and postoperatively. Consequently, mechanical support is
infrequently needed in these high-risk patients with severe
left ventricular dysfunction.
Another factor, which is important in evaluating the role
of surgical ventricular restoration, is that medical therapy
for treating CHF has advanced significantly. Randomized,
placebo-controlled blinded studies have shown that
-blockers, when added to digoxin, diuretics, and angioten-
sin-converting enzyme inhibitors, decreased mortality by at
least 30%, with annual mortality rates for patients with class
II and III CHF on -blockers less than 15%. In addition,
there is similarly impressive reduction in frequency of hos-
pitalizations for cardiovascular diseases and decreased pro-
gression for CHF. Furthermore, trials of coronary bypass
grafting with left ventricular failure in which ejection frac-
tion is less than 35% show low operative mortality (3%)
and 65% to 75% 5-year survival.2,26 Despite these encour-
aging survival results, approximately 50% of patients have
CHF at the 5-year follow-up interval,26 and 10-year mor-
tality is 60% to 80% if ejection fraction is either less than
35% or less than 25%.2
In 1998, an international cooperative effort of surgeons
and cardiologists to investigate the surgical vascular resto-
ration (surgical ventricular restoration) procedure was orga-
nized to include leading centers in the United States, Eu-
rope, Asia, and South America. Nine centers have collected
and shared information on 439 consecutive patients under-
going the surgical ventricular restoration procedure.27 The
team is called RESTORE (rebuilding normal elliptical ar-
chitecture). The mean ( SD) age of these patients was
63  10 years; baseline ejection fraction was 28%  10%
with a median LVESVI of 110 mL/m2. Akinesia was
present in 67% and dyskinesia in 33%. One hundred one of
the patients (23%) also had mitral valve repair and 96% had
bypass grafting. Only 7% required intra-aortic balloon
pumping. Operative mortality was 5.7%, estimated 1.5-year
mortality was 10%, and rehospitalization for CHF was 7%.
Postoperative ejection fraction was 39%  12.6% (an in-
crease of 10.5  0.5 percentage points) with a median
LVESVI of 68 mL/m2 (a 34.5-mL/m2 decrease).
The left ventricular shape, independent of ejection frac-
tion, defines prognosis after surgical treatment to restore a
smaller size and increase elliptical shape during rest and
exercise. The operative mortality was only 5.7% in 439
patients in a recent series, yet the large left ventricular
shape, even after successful surgical treatment of the three
components in CHF (coronary bypass grafting, mitral valve
repair, and left ventricular shape) determined long-term
prognosis after follow-up over 10 years in all survivors
(Figure 3).
Studies of left ventricular shape in the RESTORE pa-
tients, which supplement the extensive experience of Vin-
cent Dor and Marisa Di Donato, show surgical restoration of
size will reduce LVESVI from 110 to 68 mL/m2. Our
collaborative surgical/medical team has taken the steps sug-
gested in my editorial in 1998,28 in which restoration be-
comes a component of surgical treatment of the failing
akinetic heart. The extent of postoperative reduction is
related to initial LVESVI. Clearly, the extent of irreversible
changes from chronic dilatation leading to remote muscle
scar will become greater as the volume of viable muscle
becomes larger. Conversely, the incidence of CHF and
mortality without restoration exceeds 30% in 1 year if
LVESVI is more than 60 mL/m2 immediately after myo-
cardial infarction.15 These LVESVI signposts immediately
after infarction can be useful to both treat CHF and predict
Figure 3. Relationship between preoperative LVESVI (mL/m2) and
survival to 10 years. Note increased long-term survival if LVESVI
is more than 120 mL/m2. These patients underwent surgical ven-
tricular restoration at Centre Cardiothoracique de Monaco by Dor.
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CHF in left ventricles with systolic dysfunction and in-
creased volume. A change in geometry may occur in postin-
farction patients undergoing revascularization with a large
ventricle before CHF symptoms develop.
Restoration: Hibernation and Mitral Valve
The surgical rebuilding of left ventricular volume excludes
the infarct region that can be dyskinetic, akinetic, or signif-
icantly hypokinetic from epicardial viability from recent
revascularization.14 The restoration value of exclusion be-
comes even more apparent if LVESVI is greater that 75
mL/m2 and positron emission tomography or dopamine
viability exists in a nonfunctioning or severely hypokinetic
scar that is conventionally thought to be hibernating. Re-
vascularization alone does not change left ventricular vol-
ume11 in large ventricles (75 mL/m2) so that the potential
area of regional hibernation does not recover. In small
hearts (75 mL/m2) the delay of increased contraction of
the infarcted region is 1 to 6 months. Only then increased
regional shortening of remote muscle follows to improve
ejection fraction. In contrast, exclusion of the nonfunctional
area restores immediate contractility (independent of initial
volume)25 because the left ventricular size is reduced sur-
gically, the remote muscle develops a reduced radius and
becomes thickened, and ejection fraction rises immediately
after the restoration procedure.
Currently, there is a “biphasic approach” toward either
the mitral valve or the ventricle. Mickleborough and asso-
ciates23 deal with the left ventricle and do not change the
mitral valve. In contrast, Bolling and associates4 changed
the mitral valve and did not change the ventricle. They
reported reduced sphericity, increased New York Heart
Association function, and low operative mortality, but the
5-year results showed approximately 50% mortality. Left
ventricular volumes were not reported, and I presume that
changes in cardiac size accounted for the late mortality.
These results paralleled late valve replacement (aortic and
mitral) results, with approximately 60% mortality if ejection
fraction was less than 40%, even though the surgical pro-
cedures provided a perfectly competent valve.3
It seems clear that the large ventricle determines ultimate
prognosis. Mitral insufficiency is a dynamic process that
worsens with exercise, as the left ventricle dilates and
changes tethering of the chords and papillary muscle to
decrease coaptation. Certainly, left ventricular restoration
improves mitral valve function (81%), yet some insuffi-
ciency persists.23 Consequently, the residual insufficiency
can produce a secondary increase in cavitary size that can
potentially offset the value of restoration unless both mitral
and ventricular aspects are corrected. The surgical approach
to CHF is therefore a trilogy to deal with the vessels, valve,
and ventricle.
Evaluation Changes
Classic symptoms of CHF (fatigue or shortness of breath)
can be characterized most clearly through physiologic mea-
surements of peak oxygen uptake—how cardiac output
increases to deliver flow to meet metabolic needs with
exercise. This physiologic measurement of peak oxygen
consumption correlates with progression of, at rest, left
ventricular size/time in patients with CHF (independent of
resting ejection fraction or volume) and progressive mortal-
ity.29 After conventional medical treatment (angiotensin-
converting enzyme inhibitors, -blockers) mortality is high
at 18% if oxygen consumption increases, and doubles to
approximately 40% if oxygen consumption falls during
sequential yearly measurements.16,29 Of equal importance to
resting shape, the dynamic shape with exertion determines
exercise capacity.30 Oxygen consumption rises if the left
ventricle becomes more elliptical (reduced LVESVI) and
falls if the left ventricle becomes more spherical (increased
LVESVI). The measurement provides a physiologic marker
of ventricular mechanics for CHF progression. A more
elliptical shape during systole improves fiber orientation to
augment ejection (ie, MRI twisting).30 Similarly, early dia-
stolic filling needed to augment venous return for cardiac
output is enhanced after increased ellipse during exercise;
demonstrating untwisting on MRI will improve diastolic
suction.31
Approximately 30% of patients with an ejection fraction
of less than 35% in a recent series had moderate (2) mitral
regurgitation with increased spherical chamber formation.27
Exercise capacity (ie, peak oxygen consumption) is reduced
if there is only mild (1) mitral regurgitation under resting
conditions.32 Mild mitral regurgitation at rest restricts oxy-
gen consumption during exercise and thereby accounts for
the increased CHF symptoms during exertion. This physi-
ologic measurement may be useful in preoperative predic-
tion of need for mitral valve repair in patients undergoing
coronary bypass alone or in combination with a restoration
procedure.
Arrhythmic Approaches
The predominant cause of late death in CHF is either
progressive hemodynamic deterioration or sudden death.
Distention is a key factor to late arrhythmia development. In
the past, correction of electrophysiologic defects responsi-
ble for sudden death included cryotherapy to the unexcluded
muscle and endocardiectomy. This method was used by
Mickleborough23 and Dor,25 resulting in few patients dying
of late ventricular tachycardia. The role of decompression
alone in reducing late arrhythmias is not yet known. Many
surgeons test patients postoperatively by programmed ven-
tricular stimulation and insert an automatic implantable
cardiac defibrillator or use antiarrhythmic drugs. Subse-
quent comparisons will define which approach is more
appropriate.
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This geometric change in mechanical muscle formation
markedly diminishes the requirements for electrical treat-
ment of heart failure. Wrapping the muscle, cardiomyo-
plasty, is not needed because volume is diminished surgi-
cally. Automatic implantable cardiac defibrillators are
uncommon, due to diminished dilatation and resultant ec-
topy. Increased pulmonary artery pressure becomes limited,
because function of the left and right sides of the heart is
improved by restoring an elliptical shape. Consequently,
electrical monitoring of pulmonary artery pressure to avoid
rehospitalization becomes uncommon. The septum of the
restored heart beats spontaneously immediately after the
operation if myocardial protection is adequate.33 Conse-
quently, the need for biventricular pacing is limited or
avoided.
The Future
We must more properly measure how the left ventricle
functions to eject and fill. This amends standard clinical
signs of dyspnea, fatigue, and edema. Sufficient twisting for
ejection must provide enough cardiac output to meet meta-
bolic needs during exercise, while appropriate untwisting
for suction of venous return avoids raised filling pressure to
cause lung congestion. These consequences of ejection and
filling are not currently measured but are achievable through
evaluating peak oxygen uptake during exercise and nonin-
vasive pulmonary artery pressure by echocardiography. Or-
ganized use of these available evaluation methods can en-
large precision in the extent of CHF and its alteration by
treatment.
I have summarized 3 events (Tables 1 and 2) that reflect
a fundamental alteration in how the ventricle is viewed (ie,
change from only fiber shortening to include evaluation of
size and shape), how dysfunction is treated (ie, evaluating
how geometric changes of size complement conventional
medical and surgical treatment), and how treatment is eval-
uated by supplementing symptomatic assessment by mea-
suring peak oxygen uptake during exercise.
These geometric observations on the mechanical adjust-
ment may reduce the current symptomatic treatment of the
consequent disease of a spherical heart. The surgical resto-
ration of the left ventricular ellipse may reduce the extraor-
dinary expansion of drugs, surgery, and electrical devices
toward morbidity and mortality related to focus only on
remodeling away from normal. The mechanical solution of
that course needs further testing. All must recognize the
normal cardiac helical structure, and our interest is to strive
to restore the geometric configuration responsible for heart
function. This may augment reserve and may avoid medical,
surgical, electrical, and health care costs currently related to
only reducing morbidity. The hope is to separate this treat-
ment from the present mortality and morbidity end point,
where the disease is left intact, but only modified. Our
central focus may change, but this can occur only when we
begin to understand, and then restore, the normal structure
with its attendant functional counterpart. Normality, rather
than less disease, should prevail to achieve the solution to
CHF.
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